Prediction Value of XRCC 1 Gene Polymorphism on the Survival of Ovarian Cancer Treated by Adjuvant Chemotherapy

Abstract

<br/><b>Objective</b>: We conducted a prospective study to test the association between three amino acid substitutionpolymorphismic variants of DNA repair genes, XRCC1 (Arg194Trp), XRCC1(Arg280His) and XRCC1(Arg399Gln), and clinical outcome of ovarian cancer patients undergoing adjuvant chemotherapy. <br/><b>Methods</b>:195 patients with primary advanced ovarian cancer and treated by adjuvant chemotherapy were included in ourstudy. All were followed-up from Jan. 2007 to Jan. 2012. Genotyping of XRCC1 polymorphisms was conductedby TaqMan Gene Expression assays. <br/><b>Results</b>: The XRCC1 194 Trp/Trp genotype conferred a significant riskof death from ovarian cancer when compared with Arg/Arg (HR=1.56, 95%CI=1.04-3.15). Similarly, thosecarrying the XRCC1 399 Gln/Gln genotype had a increased risk of death as compared to the XRCC1 399Arg/Arg genotype with an HR (95% CI) of 1.98 (1.09-3.93). <br/><b>Conclusion</b>: This study is the first to provide evidencethat XRCC1 gene polymorphisms would well be useful as surrogate markers of clinical outcome in ovariancancer cases undergoing adjuvant chemotherapy.